Zimmer Biomet Holdings Inc (ZBH)

The liquidity ratios for Zimmer Biomet Holdings Inc show fluctuations over the past five years.

1. Current Ratio:
The current ratio measures the company's ability to cover its short-term liabilities with its short-term assets. Zimmer Biomet's current ratio has varied from 1.37 in 2019 to 1.99 in 2020. A ratio above 1 indicates that the company has more current assets than current liabilities. The decreasing trend from 2020 to 2023 may indicate that the company's short-term solvency position has weakened over the years, although the current ratio is still above 1, providing a buffer against short-term liquidity risks.

2. Quick Ratio:
The quick ratio, also known as the acid-test ratio, provides a more stringent measure of liquidity as it excludes inventory from current assets. Zimmer Biomet's quick ratio ranged from 0.68 in 2019 to 1.03 in 2020. A ratio above 1 implies that the company can meet its short-term obligations without relying on the sale of inventory. The downward trend in the quick ratio from 2020 to 2023 suggests a potential decrease in the company's ability to cover its short-term liabilities with its most liquid assets.

3. Cash Ratio:
The cash ratio is the most conservative liquidity ratio as it measures the company's ability to cover its current liabilities with cash and cash equivalents alone. Zimmer Biomet's cash ratio ranged from 0.27 in 2023 to 0.46 in 2020. A ratio below 1 indicates that the company does not hold enough cash to cover its short-term obligations entirely. The decreasing trend in the cash ratio from 2020 to 2023 suggests a potential reduction in the company's ability to generate sufficient cash to meet its immediate payment obligations.

In summary, while Zimmer Biomet has maintained current ratios above 1 over the years, indicating a buffer against short-term liquidity risks, the decrease in quick ratios and cash ratios from 2020 to 2023 suggests a potential weakening in the company's ability to meet its short-term obligations with its most liquid assets and cash reserves.

---

Additional liquidity measure

The cash conversion cycle of Zimmer Biomet Holdings Inc has shown some fluctuations over the past five years. In 2023, the cash conversion cycle increased to 417.07 days from the previous year's 396.74 days. This indicates that Zimmer Biomet took longer to convert its investments in inventory and receivables into cash in 2023.

Comparing to previous years, the cash conversion cycle in 2023 is higher than in 2021 and 2019, indicating a potential decrease in efficiency in managing working capital. However, it is lower than in 2020, which suggests an improvement in the efficiency of Zimmer Biomet's working capital management compared to that year.

In summary, Zimmer Biomet Holdings Inc's cash conversion cycle has fluctuated over the past five years, with 2023 reflecting a slightly longer cycle than the previous year. This metric is important for assessing the efficiency of converting investments in inventory and receivables into cash and may indicate potential areas for improvement in working capital management.